Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - ONA
Links shared publicly online about this topic.
- 240total visits
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - ONA
View full resource at oncologynurseadvisor.com
Tags: Cancer, Colorectal Cancer Medication, Ovarian Cancer, Disease and Condition, Phase 3 Clinical Trial, Women's Health, Avastin, disease
Most Recently Shared on June 5, 2011 at 6:30 pm By:
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent… http://goo.gl/fb/oUkM7
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - MPR
empr.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.” View full resource at empr.com
Most Recently Shared on June 5, 2011 at 6:53 pm By:
#asco2011 Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in… http://goo.gl/fb/MUWQq
Advertisement
